dc.contributor.author
Maurer, Marcus
dc.contributor.author
Costa, Celia
dc.contributor.author
Gimenez Arnau, AnaMaria
dc.contributor.author
Guillet, Gerard
dc.contributor.author
Labrador‐Horrillo, Moises
dc.contributor.author
Lapeere, Hilde
dc.contributor.author
Meshkova, Raisa
dc.contributor.author
Savic, Sinisa
dc.contributor.author
Chapman‐Rothe, Nadine
dc.date.accessioned
2022-02-15T12:56:12Z
dc.date.available
2022-02-15T12:56:12Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/34009
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-33727
dc.description.abstract
Background: Real-world evidence describing the benefits of recommended therapies and their impact on the quality of life (QoL) of chronic urticaria (CU) patients is limited.
Objective: To investigate disease burden, current treatment schedule, and the use of clinical resources by patients with H1 -antihistamine-refractory CU in Europe.
Methods: AWARE (A World-wide Antihistamine-Refractory chronic urticaria patient Evaluation) is a global, prospective, non-interventional study in the real-world setting, sponsored by the manufacturer of omalizumab. Disease characteristics, pharmacological treatments, and health-related QoL of patients (N = 2727) ≥18 years of age diagnosed with H1 -antihistamine-refractory chronic spontaneous urticaria (without inducible urticaria) for >2 months are reported here.
Results: Of the 2727 patients included, 1232 (45.2%) and 1278 (46.9%) were successfully followed up for any assessment and for the key outcome, the urticaria control test (UCT) score, respectively, and patients with complete remission (14.1%) were excluded from analyses.The proportion of patients with uncontrolled CSU (UCT score <12) dropped from 78% (n/N = 1641/2104) at baseline to 28.7% (n/N = 269/936) after two years of participation in the AWARE study. In addition, the proportion of patients with no impact of CSU on their QoL (assessed by the Dermatological Life Quality Index) increased to 57% (n/N = 664/1164) from 18.7% (n/N = 491/2621) at baseline. Emergency room visits (2.4% [n/N = 7/296] vs 33.5% [n/N = 779/2322]) and hospital stays (1.7% [n/N = 5/296] vs 24.2% [n/N = 561/2322]) reduced at Month 24 vs baseline. Overall, 23.2% (n/N = 26/112) patients on non-sedating H1 -antihistamines (nsAH) and 41.9% (n/N = 44/105) patients on up-dosed nsAH had uncontrolled CSU (UCT <12) at Month 24. In omalizumab-treated patients, 27.1% (n/N = 78/288) had uncontrolled CSU at Month 24.
Conclusion: These data confirm improvements for most patients with CSU over a 2-year follow-up period. Further studies are needed to understand the differences between guideline recommendations and reported management.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
chronic spontaneous urticaria
en
dc.subject
quality of life
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Antihistamine‐resistant chronic spontaneous urticaria remains undertreated: 2‐year data from the AWARE study
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.doi
10.1111/cea.13716
dcterms.bibliographicCitation.journaltitle
Clinical & Experimental Allergy
dcterms.bibliographicCitation.number
10
dcterms.bibliographicCitation.originalpublishername
Wiley
dcterms.bibliographicCitation.pagestart
1166
dcterms.bibliographicCitation.pageend
1175
dcterms.bibliographicCitation.volume
50
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.funding
DEAL Wiley
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
32735720
dcterms.isPartOf.issn
0954-7894
dcterms.isPartOf.eissn
1365-2222